Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Antibody Therapy With Alemtuzumab, Rituximab and GM-CSF for Initial Treatment of High Risk Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving monoclonal antibody therapy together with GM-CSF may be an effective treatment for early-stage chronic lymphocytic leukemia.
PURPOSE: This phase II trial is studying the side effects of giving rituximab and alemtuzumab together with GM-CSF and to see how well it works in treating patients with early-stage chronic lymphocytic leukemia.
調査の概要
詳細な説明
OBJECTIVES:
Primary
- To assess the rate of complete and overall response in patients with high-risk, early-stage, chronic lymphocytic leukemia (CLL) treated with alemtuzumab, rituximab, and sargramostim (GM-CSF).
- To monitor and assess toxicity of this regimen in these patients through clinical evaluation and serial monitoring of cytomegalovirus antigenemia by polymerase chain reaction (PCR).
Secondary
- To determine the overall and progression-free survival, time to response, time to next treatment, and duration of response in patients treated with this regimen.
- To assess the correlation between individual prognostic markers (i.e., 17p-, 11q-, unmutated VH gene, use of VH3-21, ZAP70+, CD38+) and clinical outcome.
Correlative Studies
- To assess response in these patients using an expanded definition of response, including minimal residual disease (MRD) by sensitive flow cytometry in patients in complete clinical remission.
- To assess MRD status of responding patients using sensitive flow cytometry and molecular assays (i.e., spectral karyotype analysis of CLL cells) before treatment and at relapse to identify subpopulations that could contribute to disease resistance and relapse.
- To detail the in vivo effect of this regimen on critical aspects of the immune system in CLL.
- To determine if GM-CSF, β-glucan, and CpG7909 can increase antibody dependent cellular cytotoxicity to improve efficacy against CLL cells and clinical response to treatment.
OUTLINE: Patients receive rituximab IV over 30 minutes on day 3 of weeks 2-5, alemtuzumab subcutaneously (SC) on days 3, 4, and 5 in week 1 and on days 1, 3, and 5 in weeks 2-5, and sargramostim SC on days 1, 3, and 5 in weeks 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients undergo blood sample collection for measurement of serum cytomegalovirus DNA copy number by polymerase chain reaction at baseline, weekly during treatment, and monthly for the 6 months after completion of treatment. Patients also undergo bone marrow biopsy and aspirate at two months and then again at 12 months (if in complete remission). Blood samples are collected periodically during study for evaluation of prognostic biomarkers (i.e., 11q-, 17p-, unmutated IgVH gene, VH3-21 gene segment use, and CD38 and ZAP-70 expression) by fluorescent in situ hybridization (FISH) and for immunophenotyping by flow cytometry. Blood samples are collected from patients at the Mayo Clinic Rochester site at baseline and periodically during study for immunological and other correlative studies, including minimal residual disease (in responding patients only).
After completion of study therapy, patients are followed periodically for up to 5 years.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Scottsdale、Arizona、アメリカ、85259-5499
- Mayo Clinic Scottsdale
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
Diagnosis of chronic lymphocytic leukemia (CLL) meeting the following criteria:
- Minimum threshold peripheral blood lymphocyte count 5 x 10^9/L
Monoclonality (light chain exclusion) of B lymphocytes detected by immunophenotyping (CD19-positive), demonstrating ≥ 3 of the following characteristics:
- CD5-positive
- CD23-positive
- Dim surface light chain expression
- Dim surface CD20 expression
- Negative for IGH/CCND1 translocation AND/OR immunostaining is negative for cyclin D1 expression by fluorescent in-situ hybridization (FISH) analysis
- Rai stage 0, I, or II disease that does not meet standard NCI-Working Group criteria for treatment of CLL
Poor prognosis as defined by ≥ 1 of the following factors:
- Unmutated IgVH mutation status AND CD38 expression (i.e., ≥ 30% cells positive on flow cytometry)
- Unmutated IgVH mutation status AND ZAP-70 expression (i.e., ≥ 20% cells positive on flow cytometry)
- VH3-21 gene segment use irrespective of mutation status AND CD38 expression (≥ 30% cells positive on flow cytometry)
- VH3-21 gene segment use irrespective of mutation status AND ZAP-70 expression (≥ 20% cells positive on flow cytometry)
- 11q-negative*
- 17p-negative* NOTE: *Determination of IgVH mutation status is not required in patients whose eligibility is based on 17p13- or 11q22- deletions
PATIENT CHARACTERISTICS:
- ECOG performance status 0- 2
- Creatinine ≤ 1.5 times upper limit of normal (ULN)
- Total bilirubin ≤ 3.0 times ULN OR direct bilirubin ≤ 1.5 ULN
- AST ≤ 3.0 times ULN (unless due to hemolysis or CLL)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must practice effective contraception
- Willing to provide mandatory blood samples (for patients at the Mayo Clinic in Rochester only) for research studies as required by the protocol
No comorbid conditions, including any of the following:
- New York Heart Association Class III or IV heart disease
- Myocardial infarction within the past month
- Uncontrolled infection
- HIV infection or AIDS
- Serological evidence of active hepatitis B infection (i.e., serum antigen or e-antigen positivity) or positive hepatitis C serology
- No other active primary malignancy requiring treatment or limiting survival to ≤ 2 years
- No active autoimmune hemolytic anemia, immune thrombocytopenia, or pure red blood cell aplasia
PRIOR CONCURRENT THERAPY:
- More than 4 weeks since prior major surgery
- No prior chemotherapy or monoclonal antibody treatment for CLL
- No concurrent corticosteroids
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Alemtuzumab + Rituximab + GM-CSF
|
Week 1 (dose escalation): Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously Weeks 2-5: 30mg subcutaneously three times a week. Weeks 2-5: 375 mg/m^2 by IV once weekly Week 1-6: 250 mcg subcutaneously three time as week
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months
時間枠：6 months
|
Response, as defined by the National Cancer Institute Working Group (NCIWG), requires the following for a period of at least 2 months:
|
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival
時間枠：Time from registration to progression (up to 5 years)
|
Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first.
Progression is defined according to the standard NCI-WG96 criteria.
The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.
|
Time from registration to progression (up to 5 years)
|
|
Duration of Response
時間枠：time from start of response to progression (up to 5 years)
|
Duration of response (DOR) is defined as the time from documentation of response (CR or PR) to disease progression. The median DOR with 95% CI was estimated using the Kaplan Meier method.Response, as defined by the National Cancer Institute Working Group (NCIWG), requires the following for a period of at least 2 months:
|
time from start of response to progression (up to 5 years)
|
|
Time to Next Treatment
時間枠：time from end of protocol treatment to subsequent treatment (up to 5 years)
|
Time to next treatment was defined as the time from end of active (protocol) treatment to the start of subsequent treatment.
The median and 95% CI was estimated using the Kaplan Meier method.
|
time from end of protocol treatment to subsequent treatment (up to 5 years)
|
|
Overall Survival
時間枠：Time from registration to death (up to 5 years)
|
Overall Survival (OS) was defined as the time from registration to death of any cause.
Participants were followed for a maximum of 5 years from registration.
The median OS with 95% CI was estimated using the Kaplan Meier method.
|
Time from registration to death (up to 5 years)
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CDR0000574754
- P30CA015083 (米国 NIH グラント/契約)
- MC0785 (その他の識別子：Mayo Clinic Cancer Center)
- U4449s (その他の識別子：Genentech)
- 001.0888 (その他の識別子：Bayer)
- 07-002087 (その他の識別子：Mayo Clinic IRB)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Alemtuzumabの臨床試験
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN); Blood and Marrow Transplant...募集